Theratechnologies Inc T.TH

Great opportunity!

[SABBOBCAT]

I feel this may make me sound like SPECO, but these opportunities don't come along very often. We are able to pick up shares at roughly 1x forward revenues right now which is a steal of a deal. 

I have been passivly adding to my position as the indescriminent tax loss sellers are met with a dearth of buyers which is driving the price down. This is frustrating for some, but please consider tthe following two things:

1) Friday Dec 23rd is the last day for tax loss selling with standard T+3 settlement for 2022.
2) There is an tranche of options expiring on tuesday Dec 20th with a $0.38 strike price.

This means that this buying "opportunity" will only last for another week to 10 days before the reversal starts. It may not come roaring back, but the price should stabalize and once the newsflow starts back up. Best case is the market takes the option exercise as positive and we se a nice pop next week, but im not holding my breath. 

The question is? Do you have the conviction to add down here? For me, the answer is yes.

[canadapiet]

Fair enough and really hope it will "fortune" you! But, but, allready 2(3?) years in negotiations (Chinese partner??)??? for Nash???? and still nothing....... No insiders willing to buy at these depressed levels.......(hey, a decent buy) No Cash!!!! I think some other companies are in a better position....... But then all of a sudden they come up with the negotiated newer

[Trogarzon]

At 3$ I agree with you.. thera better opportunites.. even at 2$... but being at 1$ if mind boggling and the Key to insanity in my book... lol 

[SABBOBCAT]

I agree it isnt without its caveats and concerns. Would I add at higher prices? Definitiely not, I already have enough exposure. However, at these levels it is like salvage value. A few thoughts on the opportunities and partnerships.  NASH: I feel that the Pandemic really did drag any progress on this. There was risk on top of risk that hampered any partnership. Then there was they

[Wino115]

It will be important for CEO to show sales did hit their target with around 15% growth last year, and to put an achievable target out for next year and exceed it - start on the low side. That will help build confidence around the drug sales. Using that opportunity to review their path to breakeven would help even more if they have it analyzed by then. He said that was his plan and there was buy-in

[houbahop]

For the First 3 quarters of 2022: Operation cash ouflow was $19.8m before balance sheet items. During that period, R&D was $27.5m They would need to scrap 25%  of their R&D to achieve breakeven, 55% to achieve $10m Net Operating Cash Flow. Some cuts in the SG&A ($72.5m in the first three quarters) would make sense but seems well protected. It won't happen until they have

[Wino115]

You have to figure in the change in the balance sheet since it either gives you cash (like lower inventories), or uses your cash. Only way to figure full operational cash flow. So despite the $19mil income statement use of cash, the balance sheet freed up $13mil so net cash usage in ops was $6mil. Cash actually increased over the 9 months because of the small net financing between loan and bond

[houbahop]

"You have to figure in the change in the balance sheet since it either gives you cash (like lower inventories), or uses your cash. Only way to figure full operational cash flow...." Quite the opposite. Fluctuations in balance sheet items is noise when you analyse CFFO.

[PWIB123]

I prefer Free Cash Flow as a measure, but we still need to understand the impact of interest expense as the company has already put a debt financing deal on the table.  You have to give consideration to working capital and those balance sheet items are not just noise.  You sell inventory, you have to buy more inventory.  You use cash by extending terms with A/R, and you may not have

[palinc2000]

My preference is simply funds from operations ....if there is a need to increase inventories because of higher sales the source of funds will be from operations...Moreover changes in working capital are caused by timing difference  ...delauying [ayment of payables near the end of one period leaves you with more cash but the reverse happens during the subsequent period because payables

[Trogarzon]

The only guy who could have put this plan together was the former CEO Luc... he's gone thanks to this board.  We now have a CEO that has a tought time living without what is called a cheif of staff..ok.  We now have a new reality that almost excludes R&D after repositioning the company from specialty pharma to an R&D shop and then to an hybryd model and to now to specialty

[Momo25]

Share will continue to drop until the end of January because inflation is now a bit under control. Stock market will start recovering especially in the mining and financial sectors. No one will put a penny on TH because there are plenty of opportunities awaiting . So the drop of TH share will continue for a while until they announce a 4th quarter. By then the share price will be below 1 buck. only